Koichi Goto

Koichi Goto, MD, PhD is Chief of the Department of Thoracic Oncology at the National Cancer Center Hospital East (Kashiwa, Japan), one of Japan's leading lung cancer centers. He is Japan's foremost expert on biomarker-driven precision oncology in non-small cell lung cancer and has been a principal investigator for numerous landmark trials including LIBRETTO-321 (selpercatinib in RET fusion-positive NSCLC in Japan), MARIPOSA (amivantamab + lazertinib in EGFR-mutant NSCLC), and multiple FGFR inhibitor trials. His work has been instrumental in characterizing the prevalence and clinical relevance of FGFR1-4 alterations in Japanese lung cancer patients and in establishing companion diagnostic frameworks for FGFR-targeted therapies in the Japanese regulatory context. Goto has contributed extensive data on the frequency of actionable biomarkers—including NTRK fusions, RET fusions, MET exon 14 skipping, and FGFR alterations—in East Asian lung cancer populations, informing region-specific testing guidelines. He has published over 200 peer-reviewed articles and serves on multiple international lung cancer guideline committees.